Advertisement
Teva Pharmaceutical Industries selected Ness, a leading provider of ITservices and solutions in Central and Eastern Europe, an Oracle PlatinumPartner and one of the region's leaders in the manufacturing segment, basedon its reputation as a reliable and proven partner who could completelyfulfill Teva's expectations regarding the new enterprise system. Key factorsfor Teva were Ness' experience in similar international projects, itsprofessional approach and its large team of dedicated Oracle E-Business Suiteexperts in Central and Eastern Europe.
Advertisement
"Our company is strongly export focused, exporting over 80% of ourproduction, including to the highly complex markets in the U.S. and WesternEurope," said Jiri Urbanec, CEO of Teva Czech Industries. "Thanks to thelaunch of a new plant for solid pharmaceutical drugs this year, we expectthat our exports will increase more than three times. In order to producefour billion tablets annually for one of the toughest markets in the world,we need to manage our financial and logistics processes with world-classtools. The new system will not only simplify and optimize Teva's productionplant in Opava, Czech Republic, and its commercial units in Prague, CzechRepublic, and Bratislava, Slovakia, but it will also connect the two Europeancountries to the Israeli offices of its parent company, Teva PharmaceuticalIndustries."
"Winning this important project confirms our dominant position as aprovider of Oracle E-Business Suite implementation services in the CzechRepublic. This is one of the most important projects of this type," saidMirko Kalous, MBA, CEO of Ness Czech. "We have been engaged with the OracleE-Business Suite since its entry into the Czech market 1993, when weparticipated in the localization and the first implementations of thesolution."
Ness has deployed and operated similar solutions for other leadingcompanies in their sectors, such as Vitkovice and Dalkia Czech Republic.Manufacturing is an important sector for Ness, where the company has a widedomain expertise. This expertise will be used by Ness in the Teva project.The cooperation between Teva and Ness is not limited only to the Czechmarket; as a regional partner Ness is able to support Teva's strategythroughout the whole region.
The Oracle E-Business Suite is a comprehensive suite of integrated,global business applications, which provides a complete, integrated businessintelligence portfolio, the most adaptable global business platform, and themost customer-focused applications strategy. The Oracle E-Business Suiteenables, for example, asset life cycle management, customer relationshipmanagement, enterprise resource planning, supply chain management and more.
About Ness Technologies
Ness Technologies (NASDAQ: NSTC and TASE: NSTC) is a global provider ofIT and business services and solutions with specialized expertise in softwareproduct engineering; system integration, application development andconsulting; and software distribution. Ness delivers its portfolio ofsolutions and services using a global delivery model combining offshore,near-shore and local teams. With about 7,800 employees, Ness maintainsoperations in 18 countries, and partners with numerous software and hardwarevendors worldwide. For more information about Ness Technologies, visithttp://www.ness.com.
About Teva Czech Industries
Teva Czech Industries, based in Opava, Czech Republic, is a leadingpharmaceutical manufacturer with a long history. Its broad portfolio includesgeneric medicines, over the counter drugs, active pharmaceutical ingredientsand plant extracts. The company's products meet recognized quality standardsand are exported to many countries around the world, including the UnitedStates and Western Europe. Teva Czech Industries employs more than 1,000employees, helping the company reach its achievements and ambitious goals. In2006 the company became part of Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is amongthe top 20 pharmaceutical companies in the world and is a leading genericpharmaceutical company. The company develops, manufactures and marketsgeneric and innovative pharmaceuticals and active pharmaceutical ingredients.Over 80 percent of Teva's sales are in North America and Western Europe. Formore information about Teva, visit http://www.tevapharm.com.
Forward Looking Statement
This press release contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995. Forward-lookingstatements often are preceded by words such as "believes," "expects," "may,""anticipates," "plans," "intends," "assumes," "will" or similar expressions.Forward-looking statements reflect management's current expectations, as ofthe date of this press release, and involve certain risks and uncertainties.Ness' actual results could differ materially from those anticipated in theseforward looking statements as a result of various factors. Some of thefactors that could cause future results to materially differ from the recentresults or those projected in forward-looking statements include the "RiskFactors" described in Ness' Annual Report of Form 10-K filed with theSecurities and Exchange Commission on March 15, 2010. Ness is under noobligation, and expressly disclaims any obligation, to update or alter itsforward-looking statements, whether as a result of such changes, newinformation, subsequent events or otherwise.
TrademarksOracle and Java are registered trademarks of Oracle Corporation and/orits affiliates. Media Contact: David Kanaan Intl: +972-54-425-5307 Email: [email protected] Investor Relations Contact: Drew Wright USA: +1-201-488-3262 Email: [email protected]
SOURCE Ness Technologies Inc
